Biopharma & Parenterals
The rise of biologics has been a well documented phenomenon, with large pharmaceutical companies scaling up their respective biologics departments, and major mergers taking place on a regular basis. The exponential increase in the number of biologic products entering the marketplace has given rise to a host of new regulatory concerns.
As part of our continuous effort to present content devoted to the unique regulatory pathways biomanufacturers navigate throughout the product lifecycle, we are now making it easier for companies to address these concerns by providing a series of courses that are geared towards these specific regulatory & compliance requirements.
The courses listed below are truly geared towards a biologics audience, and generally cover the major requirements.
